Abstract
Diabetic retinopathy, the most common complication of diabetes, is a neurodegenerative disease in the eye. And Parkinson's disease, affecting the health of 1–2% of people over 60 years old throughout the world, is the second largest neurodegenerative disease in the brain. As the understanding of diabetic retinopathy and Parkinson's disease deepens, the two diseases are found to show correlation in incidence, similarity in clinical presentation, and close association in pathophysiological mechanisms. To reveal the association between pathophysiological mechanisms of the two disease, in this review, the shared pathophysiological factors of diabetic retinopathy and Parkinson's disease are summarized and classified into dopaminergic system, circadian rhythm, neurotrophic factors, α-synuclein, and Wnt signaling pathways. Furthermore, similar and different mechanisms so far as the shared pathophysiological factors of the two disorders are discussed systematically. Finally, a brief summary and new perspectives are presented to provide new directions for further efforts on the association, exploration, and clinical prevention and treatment of diabetic retinopathy and Parkinson's disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adachi N, Yoshimura A, Chiba S, Ogawa S, Kunugi H (2018) Rotigotine, a dopamine receptor agonist, increased bdnf protein levels in the rat cortex and hippocampus. Neurosci Lett 662:44–50. https://doi.org/10.1016/j.neulet.2017.10.006
Agostino PV, do Nascimento M, Bussi IL, Eguía MC, Golombek DA (2011) Circadian modulation of interval timing in mice. Brain Res 1370:154–163. https://doi.org/10.1016/j.brainres.2010.11.029
Alomari MA, Khalil H, Khabour OF, Alzoubi KH, Dersieh EH (2018) Altered cardiovascular function is related to reduced bdnf in Parkinson's disease. Exp Aging Res 44(3):232–245. https://doi.org/10.1080/0361073x.2018.1449589
Antonelli F, Strafella AP (2014) Behavioral disorders in Parkinson's disease: the role of dopamine. Parkinsonism Relat Disord 20:S10–S12. https://doi.org/10.1016/S1353-8020(13)70005-1
Aung MH, Park HN, Han MK, Obertone TS, Abey J, Aseem F, Thule PM, Iuvone PM, Pardue MT (2014) Dopamine deficiency contributes to early visual dysfunction in a rodent model of type 1 diabetes. J Neurosci 34(3):726–736. https://doi.org/10.1523/JNEUROSCI.3483-13.2014
Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, Whitton P, Wyse R, Isaacs T, Lees A, Limousin P, Foltynie T (2013) Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest 123(6):2730–2736. https://doi.org/10.1172/JCI68295
Baik JH (2013) Dopamine signaling in reward-related behaviors. Front Neural Circuits 7:152. https://doi.org/10.3389/fncir.2013.00152
Bearse MA Jr, Han Y, Schneck ME, Adams AJ (2004) Retinal function in normal and diabetic eyes mapped with the slow flash multifocal electroretinogram. Invest Ophthalmol Vis Sci 45(1):296–304. https://doi.org/10.1167/iovs.03-0424
Beaulieu JM, Espinoza S, Gainetdinov RR (2015) Dopamine receptors—IUPHAR review 13. Br J Pharmacol 172(1):1–23. https://doi.org/10.1111/bph.12906
Berwick DC, Harvey K (2012) LRRK2 functions as a wnt signaling scaffold, bridging cytosolic proteins and membrane-localized LRP6. Hum Mol Genet 21(22):4966–4979. https://doi.org/10.1093/hmg/dds342
Beyer K, Ispierto L, Latorre P, Tolosa E, Ariza A (2011) Alpha- and beta-synuclein expression in Parkinson disease with and without dementia. J Neurol Sci 310(1–2):112–117. https://doi.org/10.1016/j.jns.2011.05.049
Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, Guilloteau D, Crossman AR, Bioulac B, Brotchie JM, Gross CE (2001) Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 21:6853–6861. https://doi.org/10.1523/JNEUROSCI.21-17-06853.2001
Bhatwadekar AD, Yan Y, Qi X, Thinschmidt JS, Neu MB, Li Calzi S, Shaw LC, Dominiguez JM, Busik JV, Lee C, Boulton ME, Grant MB (2013) Per2 mutation recapitulates the vascular phenotype of diabetes in the retina and bone marrow. Diabetes 62(1):273–282. https://doi.org/10.2337/db12-0172
Boss JD, Singh PK, Pandya HK, Tosi J, Kim C, Tewari A, Juzych MS, Abrams GW, Kumar A (2017) Assessment of neurotrophins and inflammatory mediators in vitreous of patients with diabetic retinopathy. Invest Ophthalmol Vis Sci 58(12):5594–5603. https://doi.org/10.1167/iovs.17-21973
Bridi JC, Hirth F (2018) Mechanisms of alpha-synuclein induced synaptopathy in Parkinson's disease. Front Neurosci 12:80. https://doi.org/10.3389/fnins.2018.00080
Caravaggio F, Scifo E, Sibille EL, Hernandez-Da Mota SE, Gerretsen P, Remington G, Graff-Guerrero A (2018) Expression of dopamine D2 and D3 receptors in the human retina revealed by positron emission tomography and targeted mass spectrometry. Exp Eye Res 175:32–41. https://doi.org/10.1016/j.exer.2018.06.006
Chen Q, Ma JX (2017) Canonical Wnt signaling in diabetic retinopathy. Vision Res 139:47–58. https://doi.org/10.1016/j.visres.2017.02.007
Chen Y, Hu Y, Zhou T, Zhou KK, Mott R, Wu M, Boulton M, Lyons TJ, Gao G, Ma JX (2009) Activation of the wnt pathway plays a pathogenic role in diabetic retinopathy in humans and animal models. Am J Pathol 175(6):2676–2685. https://doi.org/10.2353/ajpath.2009.080945
Date I, Ohmoto T, Imaoka T, Ono T, Hammang JP, Francis J, Greco C, Emerich DF (1996) Cografting with polymer-encapsulated human nerve growth factor-secreting cells and chromaffin cell survival and behavioral recovery in hemiparkinsonian rats. J Neurosurg 84(6):1006–1012. https://doi.org/10.3171/jns.1996.84.6.1006
de Melo Reis RA, Ventura AL, Schitine CS, de Mello MC, de Mello FG (2008) Müller glia as an active compartment modulating nervous activity in the vertebrate retina: neurotransmitters and trophic factors. Neurochem Res 33(8):1466–1474. https://doi.org/10.1007/s11064-008-9604-1
de Araújo FM, Ferreira RS, Souza CS, Dos Santos CC, Rodrigues TL, e Silva JH, Gasparotto J, Gelain DP, El-Bachá RS, Maria de Fátima DC, Fonseca JCVDA (2018) Aminochrome decreases ngf, gdnf and induces neuroinflammation in organotypic midbrain slice cultures. Neurotoxicology 66:98–106. https://doi.org/10.1016/j.neuro.2018.03.009
De Lazzari F, Bisaglia M, Zordan MA, Sandrelli F (2018) Circadian rhythm abnormalities in Parkinson's disease from humans to flies and back. Int J Mol Sci 19(12):3911. https://doi.org/10.3390/ijms19123911
Fatima S, Haque R, Jadiya P, Shamsuzzama KL, Nazir A (2014) Ida-1, the caenorhabditis elegans orthologue of mammalian diabetes autoantigen IA-2, potentially acts as a common modulator between Parkinson's disease and diabetes: role of Daf-2/Daf-16 insulin like signalling pathway. PLoS ONE 9(12):e113986. https://doi.org/10.1371/journal.pone.0113986
Fletcher EL, Phipps JA, Ward MM, Puthussery T, Wilkinson-Berka JL (2007) Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy. Curr Pharm Des 13(26):2699–2712. https://doi.org/10.2174/138161207781662920
Gasser T (2009) Molecular pathogenesis of parkinson disease: insights from genetic studies. Expert Rev Mol Med 11:e22. https://doi.org/10.1017/S1462399409001148
Gastinger MJ, Singh RS, Barber AJ (2006) Loss of cholinergic and dopaminergic amacrine cells in streptozotocin-diabetic rat and Ins2Akita-diabetic mouse retinas. Invest Ophthalmol Vis Sci 47(7):3143–3150. https://doi.org/10.1167/iovs.05-1376
Guigoni C, Doudnikoff E, Li Q, Bloch B, Bezard E (2007) Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates. Neurobiol Dis 26:452–463. https://doi.org/10.1016/j.nbd.2007.02.001
Gu Z, Wang B, Zhang YB, Ding H, Zhang Y, Yu J, Gu M, Chan P, Cai Y (2015) Association of ARNTL and PER1 genes with Parkinson's disease: a case-control study of Han Chinese. Sci Rep 5:15891. https://doi.org/10.1038/srep15891
Hammes HP, Federoff HJ, Brownlee M (1995) Nerve growth factor prevents both neuroretinal programmed cell death and capillary pathology in experimental diabetes. Mol Med 1(5):527–534
Hood S, Cassidy P, Cossette MP, Weigl Y, Verwey M, Robinson B, Stewart J, Amir S (2010) Endogenous dopamine regulates the rhythm of expression of the clock protein PER2 in the rat dorsal striatum via daily activation of D2 dopamine receptors. J Neurosci 30(42):14046–14058. https://doi.org/10.1523/JNEUROSCI.2128-10.2010
Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J (2007) Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 30(4):842–847. https://doi.org/10.2337/dc06-2011
Ishii T, Warabi E, Mann GE (2019) Circadian control of BDNF-mediated Nrf2 activation in astrocytes protects dopaminergic neurons from ferroptosis. Free Radic Biol Med 133:169–178. https://doi.org/10.1016/j.freeradbiomed.2018.09.002
Jackson GR, Barber AJ (2010) Visual dysfunction associated with diabetic retinopathy. Curr Diabetes Rep 10(5):380–384
Jackson CR, Chaurasia SS, Hwang CK, Iuvone PM (2011) Dopamine D4 receptor activation controls circadian timing of the adenylyl cyclase 1/cyclic amp signaling system in mouse retina. Eur J Neurosci 34(1):57–64. https://doi.org/10.1111/j.1460-9568.2011.07734.x
Jackson CR, Ruan GX, Aseem F, Abey J, Gamble K, Stanwood G, Palmiter RD, Iuvone PM, McMahon DG (2012) Retinal dopamine mediates multiple dimensions of light-adapted vision. J Neurosci 32(27):9359–9368. https://doi.org/10.1523/JNEUROSCI.0711-12.2012
Jadhav V, Luo Q, Dominguez M 2nd, Al-Sabah J, Chaqour B, Grant MB, Bhatwadekar AD (2016) Per2-mediated vascular dysfunction is caused by the upregulation of the connective tissue growth factor (CTGF). PLoS ONE 11(9):e0163367. https://doi.org/10.1371/journal.pone.0163367
Kafka MS, Benedito MA, Roth RH, Steele LK, Wolfe WW, Catravas GN (1986) Circadian rhythms in catecholamine metabolites and cyclic nucleotide production. Chronobiol Int 3(2):101–115. https://doi.org/10.3109/07420528609066354
Keeler JF, Pretsell DO, Robbins TW (2014) Functional implications of dopamine D1 vs. D2 receptors: a 'prepare and select' model of the striatal direct vs. indirect pathways. Neuroscience 282:156–175. https://doi.org/10.1016/j.neuroscience.2014.07.021
Klaassen I, de Vries EW, Vogels IMC, van Kampen AHC, Bosscha MI, Steel DHW, Van Noorden CJF, Lesnik-Oberstein SY, Schlingemann RO (2017) Identification of proteins associated with clinical and pathological features of proliferative diabetic retinopathy in vitreous and fibrovascular membranes. PLoS ONE 12(11):e0187304. https://doi.org/10.1371/journal.pone.0187304
Kudo T, Loh DH, Truong D, Wu Y, Colwell CS (2011) Circadian dysfunction in a mouse model of Parkinson's disease. Exp Neurol 232(1):66–75. https://doi.org/10.1016/j.expneurol.2011.08.003
Kusters CDJ, Paul KC, Guella I, Bronstein JM, Sinsheimer JS, Farrer MJ, Ritz BR (2018) Dopamine receptors and BDNF-haplotypes predict dyskinesia in Parkinson's disease. Parkinsonism Relat Disord 47:39–44. https://doi.org/10.1016/j.parkreldis.2017.11.339
Kwapong WR, Ye H, Peng C, Zhuang X, Wang J, Shen M, Lu F (2018) Retinal microvascular impairment in the early stages of Parkinson's disease. Invest Ophthalmol Vis Sci 59(10):4115–4122. https://doi.org/10.1167/iovs.17-23230
Lahouaoui H, Coutanson C, Cooper HM, Bennis M, Dkhissi-Benyahya O (2016) Diabetic retinopathy alters light-induced clock gene expression and dopamine levels in the mouse retina. Mol Vis 22:959–969
Lee SE, Han K, Baek JY, Ko KS, Lee KU, Koh EH, Taskforce Team for Diabetes Fact Sheet of the Korean Diabetes Association (2018) Association between diabetic retinopathy and Parkinson disease: the korean national health insurance service database. J Clin Endocrinol Metab 103(9):3231–3238. https://doi.org/10.1210/jc.2017-02774
Li S, Wang Y, Wang F, Hu LF, Liu CF (2017) A new perspective for Parkinson's disease: circadian rhythm. Neurosci Bull 33(1):62–72. https://doi.org/10.1007/s12264-016-0089-7
Liu Q, Zhang X, Cheng R, Ma JX, Yi J, Li J (2019) Salutary effect of fenofibrate on type 1 diabetic retinopathy via inhibiting oxidative stress-mediated Wnt/β-catenin pathway activation. Cell Tissue Res 376(2):165–177. https://doi.org/10.1007/s00441-018-2974-z
Luo D, Zhao J, Cheng Y, Lee SM, Rong J (2018) N-propargyl caffeamide (PACA) ameliorates dopaminergic neuronal loss and motor dysfunctions in MPTP mouse model of Parkinson's disease and in MPP(+)-induced neurons via promoting the conversion of proNGF to NGF. Mol Neurobiol 55(3):2258–2267. https://doi.org/10.1007/s12035-017-0486-6
Manki H, Kanba S, Muramatsu T, Higuchi S, Suzuki E, Matsushita S, Ono Y, Chiba H, Shintani F, Nakamura M, Yagi G, Asai M (1996) Dopamine D2, D3 and D4 receptor and transporter gene polymorphisms and mood disorders. J Affect Disord 40(1–2):7–13. https://doi.org/10.1016/0165-0327(96)00035-3
Mao SH, Ding MP, Huang JZ, Luo W (2005) Effect of L-dopa on cells expressing D2 receptors and level of dopamine transmitter rats. Chin Pharm J 15:1149–1151 (in Chinese)
Mathew GE, Oh JM, Mohan K, Tengli A, Mathew B, Kim H (2020) Development of methylthiosemicarbazones as new reversible monoamine oxidase-B inhibitors for the treatment of Parkinson's disease. J Biomol Struct Dyn. https://doi.org/10.1080/07391102.2020.1782266
McClung CA, Sidiropoulou K, Vitaterna M, Takahashi JS, White FJ, Cooper DC, Nestler EJ (2005) Regulation of dopaminergic transmission and cocaine reward by the Clock gene. PNAS 102(26):9377–9381. https://doi.org/10.1073/pnas.0503584102
McMahon DG, Iuvone PM, Tosini G (2014) Circadian organization of the mammalian retina: from gene regulation to physiology and diseases. Prog Retin Eye Res 39:58–76. https://doi.org/10.1016/j.preteyeres.2013.12.001
Mendoza J, Challet E (2014) Circadian insights into dopamine mechanisms. Neuroscience 282:230–242. https://doi.org/10.1016/j.neuroscience.2014.07.081
Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine receptors: from structure to function. Physiol Rev 78(1):189–225. https://doi.org/10.1152/physrev.1998.78.1.189
Morin N, Jourdain VA, Morissette M, Grégoire L, Di Paolo T (2014) Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys. Neuropharmacology 79:688–706. https://doi.org/10.1016/j.neuropharm.2014.01.014
Motz CT, Chesler KC, Allen RS, Bales KL, Mees LM, Feola AJ, Maa AY, Olson DE, Thule PM, Iuvone PM, Hendrick AM, Pardue MT (2020) Novel detection and restorative levodopa treatment for pre-clinical diabetic retinopathy diabetes. Diabetes 69(7):1518–1527. https://doi.org/10.2337/db19-0869
Müller T, Möhr JD (2018) Efficacy of carbidopa-levodopa extended-release capsules (IPX066) in the treatment of Parkinson disease. Expert Opin Pharmacother 19(18):2063–2071. https://doi.org/10.1080/14656566.2018.1538355
Müller T, Woitalla D, Muhlack S (2011) Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol 383:627–633. https://doi.org/10.1007/s00210-011-0629-7
Muthuraman M, Koirala N, Ciolac D, Pintea B, Glaser M, Groppa S, Tamás G, Groppa S (2018) Deep brain stimulation and L-DOPA therapy: concepts of action and clinical applications in Parkinson's disease. Front Neurol 27(9):711. https://doi.org/10.3389/fneur.2018.00711
Mysona BA, Matragoon S, Stephens M, Mohamed IN, Farooq A, Bartasis ML, Fouda AY, Shanab AY, Espinosa-Heidmann DG, El-Remessy AB (2015) Imbalance of the nerve growth factor and its precursor as a potential biomarker for diabetic retinopathy. Biomed Res Int 2015:571456. https://doi.org/10.1155/2015/571456
Nishikiori N, Osanai M, Chiba H, Kojima T, Mitamura Y, Ohguro H, Sawada N (2007) Glial cell-derived cytokines attenuate the breakdown of vascular integrity in diabetic retinopathy. Diabetes 56(5):1333–1340. https://doi.org/10.2337/db06-1431
Obara EA, Hannibal J, Heegaard S, Fahrenkrug J (2017) Loss of melanopsin-expressing retinal ganglion cells in patients with diabetic retinopathy. Invest Ophthalmol Vis Sci 58(4):2187–2192. https://doi.org/10.1167/iovs.16-21168
Ortuño-Lizarán I, Beach TG, Serrano GE, Walker DG, Adler CH, Cuenca N (2018) Phosphorylated α-synuclein in the retina is a biomarker of Parkinson's disease pathology severity. Mov Disord 33(8):1315–1324. https://doi.org/10.1002/mds.27392
Ory-Magne F, Corvol JC, Azulay JP, Bonnet AM, Brefel-Courbon C, Damier P, Dellapina E, Destée A, Durif F, Galitzky M, Lebouvier T, Meissner W, Thalamas C, Tison F, Salis A, Sommet A, Viallet F, Vidailhet M, Rascol O, NS-Park CIC Network (2014) Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology 82:300–307. https://doi.org/10.1080/07391102.2020.1782266
Parihar MS, Parihar A, Fujita M, Hashimoto M, Ghafourifar P (2008) Mitochondrial association of alpha-synuclein causes oxidative stress. Cell Mol Life Sci 65(7–8):1272–1284. https://doi.org/10.1007/s00018-008-7589-1
Politis M, Wilson H, Wu K, Brooks DJ, Piccini P (2017) Chronic exposure to dopamine agonists affects the integrity of striatal D2 receptors in Parkinson's patients. Neuroimage Clin 16:455–460. https://doi.org/10.1016/j.nicl.2017.08.013
Qiu F, He J, Zhou Y, Bai X, Wu G, Wang X, Liu Z, Chen Y, Ma JX, Liu Z (2014) Plasma and vitreous fluid levels of Dickkopf-1 in patients with diabetic retinopathy. Eye (London) 28(4):402–409. https://doi.org/10.1038/eye.2013.229
Qu WM, Xu XH, Yan MM, Wang YQ, Urade Y, Huang ZL (2010) Essential role of dopamine D2 receptor in the maintenance of wakefulness, but not in homeostatic regulation of sleep, in mice. J Neurosci 30(12):4382–4389. https://doi.org/10.1523/JNEUROSCI.4936-09.2010
Ribelayga C, Cao Y, Mangel SC (2008) The circadian clock in the retina controls rod-cone coupling. Neuron 59(5):790–801. https://doi.org/10.1016/j.neuron.2008.07.017
Roybal K, Theobold D, Graham A, DiNieri JA, Russo SJ, Krishnan V, Chakravarty S, Peevey J, Oehrlein N, Birnbaum S, Vitaterna MH, Orsulak P, Takahashi JS, Nestler EJ, Carlezon WA Jr, McClung CA (2007) Mania-like behavior induced by disruption of clock. PNAS 104(15):6406–6411. https://doi.org/10.1073/pnas.0609625104
Sancho RM, Law BM, Harvey K (2009) Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways. Hum Mol Genet 18(20):3955–3968. https://doi.org/10.1093/hmg/ddp337
Schernhammer E, Hansen J, Rugbjerg K, Wermuth L, Ritz B (2011) Diabetes and the risk of developing Parkinson's disease in denmark. Diabetes Care 34(5):1102–1108. https://doi.org/10.2337/dc10-1333
Seeman P (2015) Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse 69:183–189. https://doi.org/10.1002/syn.21805
Seki M, Tanaka T, Nawa H, Usui T, Fukuchi T, Ikeda K, Abe H, Takei N (2004) Involvement of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocin-induced diabetes in rats: therapeutic potential of brain-derived neurotrophic factor for dopaminergic amacrine cells. Diabetes 53(9):2412–2419. https://doi.org/10.2337/diabetes.53.9.2412
Simó R, Hernandez C (2014) European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR) Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives. Trends Endocrinol Metab 25:23–33. https://doi.org/10.1016/j.tem.2013.09.005
Simó R, Stitt AW, Gardner TW (2018) Neurodegeneration in diabetic retinopathy: does it really matter? Diabetologia 61:1902–1912. https://doi.org/10.1007/s00125-018-4692-1
Sivaprasad S, Gupta B, Crosby-Nwaobi R, Evans J (2012) Prevalence of diabetic retinopathy in various ethnic groups: a worldwide perspective. Surv Ophthalmol 57(4):347–370. https://doi.org/10.1016/j.survophthal.2012.01.004
Sleipness EP, Sorg BA, Jansen HT (2007) Diurnal differences in dopamine transporter and tyrosine hydroxylase levels in rat brain: dependence on the suprachiasmatic nucleus. Brain Res 1129(1):34–42. https://doi.org/10.1016/j.brainres.2006.10.063
Stitt AW, Curtis TM, Chen M, Medina RJ, McKay GJ, Jenkins A, Gardiner TA, Lyons TJ, Hammes HP, Simó R, Lois N (2016) The progress in understanding and treatment of diabetic retinopathy. Prog Retin Eye Res 51:156–186. https://doi.org/10.1016/j.preteyeres.2015.08.001
Sundstrom JM, Hernández C, Weber SR, Zhao Y, Dunklebarger M, Tiberti N, Laremore T, Simó-Servat O, Garcia-Ramirez M, Barber AJ, Gardner TW, Simó R (2018) Proteomic analysis of early diabetic retinopathy reveals mediators of neurodegenerative brain diseases. Invest Ophthalmol Vis Sci 59:2264–2274. https://doi.org/10.1167/iovs.17-23678
Tian T, Li Z, Lu H (2015) Common pathophysiology affecting diabetic retinopathy and Parkinson's disease. Med Hypotheses 85(4):397–398. https://doi.org/10.1016/j.mehy.2015.06.016
Tome D, Fonseca CP, Campos FL, Baltazar G (2017) Role of neurotrophic factors in Parkinson's disease. Curr Pharm Des 23(5):809–838. https://doi.org/10.2174/1381612822666161208120422
Videnovic A, Golombek D (2017) Circadian dysregulation in Parkinson's disease. Neurobiol Sleep Circadian Rhythms 2:53–58. https://doi.org/10.1016/j.nbscr.2016.11.001
Wang Q, Tikhonenko M, Bozack SN, Lydic TA, Yan L, Panchy NL, McSorley KM, Faber MS, Yan Y, Boulton ME, Grant MB, Busik JV (2014) Changes in the daily rhythm of lipid metabolism in the diabetic retina. PLoS ONE 9(4):e95028. https://doi.org/10.1371/journal.pone.0095028
Wilkerson A, Levin ED (1999) Ventral hippocampal dopamine D1 and D2 systems and spatial working memory in rats. Neuroscience 89(3):743–749. https://doi.org/10.1016/S0306-4522(98)00346-7
Witkovsky P (2004) Dopamine and retinal function. Doc Ophthalmol 108(1):17–40. https://doi.org/10.1023/B:DOOP.0000019487.88486.0a
Wong TY, Cheung CM, Larsen M, Sharma S, Simó R (2016) Diabetic retinopathy. Nat Rev Dis Primers 2:16012. https://doi.org/10.1038/nrdp.2016.12
Xiao L (1997) Status and prospect of basic research on retinal dopamine nervous system and myopia. Foreign Medical Sciences (Section of Ophthalmology) 5:306–308 (in Chinese)
Yajima Y, Narita M, Usui A, Kaneko C, Miyatake M, Narita M, Yamaguchi T, Tamaki H, Wachi H, Seyama Y, Suzuki T (2005) Direct evidence for the involvement of brain-derived neurotrophic factor in the development of a neuropathic pain-like state in mice. J Neurochem 93(3):584–594. https://doi.org/10.1111/j.1471-4159.2005.03045.x
Yuan AH, MeiY ZHY, Yang HJ (2012) Expression of synuclein proteins family in retinal tissue of diabetic rats. Rec Adv Ophthalmol 32(3):215–218 (in Chinese)
Zheng X, Huang Z, Zhu Y, Liu B, Chen Z, Chen T, Jia L, Li Y, Lei W (2019) Increase in glutamatergic terminals in the striatum following dopamine depletion in a rat model of Parkinson's disease. Neurochem Res 44(5):1079–1089. https://doi.org/10.1007/s11064-019-02739-y
Zhou T, Zu G, Zhang X, Wang X, Li S, Gong X, Liang Z, Zhao J (2016) Neuroprotective effects of ginsenoside Rg1 through the Wnt/β-catenin signaling pathway in both in vivo and in vitro models of Parkinson's disease. Neuropharmacology 101:480–489. https://doi.org/10.1016/j.neuropharm.2015.10.024
Zosen DV, Dorofeeva NA, Chernigovskaya EV, Bachteeva VT, Glazova MV (2018) Erk1/2 inhibition increases dopamine release from differentiated PC12 cells. Neurosci Lett 684:6–12. https://doi.org/10.1016/j.neulet.2018.06.056
Acknowledgements
This work was supported by the National Natural Science Foundation of China (Nos. 81660166 and 81660146), the Yunnan Science and Technology Talents and Platform Plan (No. 2019HB050), and Yunnan Youth Talent Support Program (No. YNWR-QNBJ-2018-315).
Author information
Authors and Affiliations
Contributions
ZQZ, YKZ and HYZ contributed equally to the paper. All authors read and approved of the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that there are no potential conflicts of interest.
Ethical Approval
This work does not contain any studies with human participants or animals performed by any of the authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Zhang, Z., Zhou, Y., Zhao, H. et al. Association Between Pathophysiological Mechanisms of Diabetic Retinopathy and Parkinson’s Disease. Cell Mol Neurobiol 42, 665–675 (2022). https://doi.org/10.1007/s10571-020-00953-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10571-020-00953-9